VIVUS Inc (VVUS.OQ)
|Market Cap (Mil.):||$496.94|
|Shares Outstanding (Mil.):||103.31|
(Adds Stryker, Vivus, Transcontinental, Orange, St. Jude Medical; Updates Weir, Valeant, General Electric)
- Vivus Inc's biggest shareholder said it was planning to buy the obesity drug maker in a deal valued at $640 million, the latest shareholder attempt to revive a company that has struggled to boost sales of its key drug.
May 28 - Vivus Inc's biggest shareholder said it was planning to buy the obesity drug maker in a deal valued at $640 million, the latest shareholder attempt to revive a company that has struggled to boost sales of its key drug.
* Indexes off: Dow 0.2 pct, S&P 0.1 pct, Nasdaq 0.2 pct (Updates to morning trading, adds comment, Vivus)
May 28 - Aspen Investment Fund, a shareholder of obesity drug maker Vivus Inc, said it was planning to offer to buy the company for $640 million.
|Takeda Pharmaceutical Co Ltd (4502.T)||¥4,674||+8.00|
|Eisai Co., Ltd (4523.T)||¥4,224||-1.50|
|Novo Nordisk A/S (NOVOb.CO)||kr.251.50||-4.70|
|Pfizer Inc. (PFE.N)||$30.42||-0.06|
|Merck & Co., Inc. (MRK.N)||$58.13||+0.02|
|Roche Holding Ltd. (ROG.VX)||CHF268.20||+1.70|
|GlaxoSmithKline plc (GSK.L)||1,469.50p||-12.00|
|Eli Lilly and Co (LLY.N)||$64.49||+0.24|
|Arena Pharmaceuticals, Inc. (ARNA.OQ)||$4.83||-0.05|
|Orexigen Therapeutics, Inc. (OREX.OQ)||$5.29||-0.05|
Earnings vs. Estimates
Analyst Research Reports
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report
"The Economy Matters" Report for VVUS: the economy's impact on VVUS's price and risk, featuring the powerful Economic Climate Rating
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ Quantitative Report
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.